Figure 1.
Comparison of CRISPLD2 expression in the endometrium during menstrual cycle.
(A) Quantitative real-time PCR analysis of CRISPLD2 gene expression in proliferative and secretory phase during the menstrual cycle normalized using the ddCt method to the 18S gene. The results represent the mean ± SEM. ** p<0.01. (B) Immunohistochemical analysis of CRISPLD2 in proliferative (a and b) and early (c and d), mid (e and f), and late (g and h) secretory phase of the menstrual cycle. Black arrow head indicates a decidualized cell. (C) CRISPLD2 was scored by measuring expression intensity of endometrial cells. The results represent the mean ± SEM. * p<0.05.
Figure 2.
Comparison of CRISPLD2 expression in the endometrium between women with and without diagnosed endometriosis.
(A) Immunohistochemical analysis of CRISPLD2 in paired (a - d from women without diagnosed endometriosis; e - h from women with endometriosis) endometrium. (B) CRISPLD2 was scored by measuring expression intensity of endometrial cells. The results represent the mean ± SEM. * p<0.05
Figure 3.
Comparison of CRISPLD2 expression in the endometrium between eutopic and ectopic endometriosis lesions.
(A) Representative immunohistochemistry of CRISPLD2 in eutopic and ectopic endometrium with endometriosis. (B and C) CRISPLD2 was scored by measuring expression intensity of endometrial epithelial (B) and stromal (C) cells. The results represent the mean ± SEM. *** p<0.001; * p<0.05
Figure 4.
Expression of CRISPLD2 during in vitro decidualization of hESCs.
(A to C) Expression of decidualization marker genes, IGFPB1 (A) and PRL (B) and CRISPLD2 gene (C) were examined during in vitro decidualization of hESCs. The results represent the mean ± SEM. * p<0.05; **, p<0.01; ***, p<0.001. (D) Protein level of CRISPLD2 was measured by Western blot analysis. Actin was used as loading control. Black arrow head indicates a non-secreted CRISPLD2 and white arrow head indicates secreted CRISPLD2.
Figure 5.
The expression level of Crispld2 in pregnancy and the localization pattern of CRISPLD2 during early pregnancy.
(A) The expression level of Crispld2 was measured in uteri of early pregnancy. Total RNA used for the quantitative real-time PCR assays was prepared from early pregnancy uteri. The results represent the mean ± SEM of three independent RNA sets. * p<0.05; ** p<0.01; ***; p<0.001. (B) The localization pattern of CRISPLD2 during natural pregnancy by immunohistochemistry were determined at 0.5 dpc (a and b), 2.5 dpc (c and d), 3.5 dpc (e and f), 4.5 dpc (g and h), 5.5 dpc (i and j), and 7.5 dpc (k and l). Black arrow head indicates embryo, PD means primary differentiated decidual cells, and SD means secondary decidual zone.
Figure 6.
The expression of CRISPLD2 in wild-type or PRKO mice.
(A) The expression level of Crispld2 from P4 treated wild-type or PRKO uteri by quantitative real-time PCR. Total RNA used for the quantitative real-time PCR was prepared from wild-type or PRKO uteri treated with P4 or vehicle for 6 hours. The results represent the mean ± SEM of three independent RNA sets. ** p<0.01; *** p<0.001. (B) The localization pattern of CRISPLD2 by immunohistochemistry in vehicle or P4-treated uteri. Uterine sections were collected from P4 or Veh treated wild-type (a and b) and PRKO (c and d) mice for 6 hours.
Figure 7.
The expression of CRISPLD2 by steroid hormones.
(A) The expression level of CRISPLD2 from vehicle, or estrogen (E2) treated uteri by real-time PCR. Total RNA used for the real-time PCR assays was prepared from ovariectomized wild-type C57BL/6 mice treated with vehicle, E2, or E2+P4 for 6 hours. The results represent the mean ± SEM of three independent RNA sets. * p<0.5; ** p<0.01. (B) The localization pattern of CRISPLD2 by immunohistochemistry in vehicle, E2, or E2+P4 treated wild-type mice uteri for 6 hours. Nuclei were counterstained with hematoxylin.